Associated Papers
Insight into the role of PCSK9 in glucose metabolism.
Xu JN et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2023
Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.
Sarkar SK et al.
Frontiers in Physiology, 2022
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology.
Sundararaman SS et al.
Biomedicines, 2021
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk W et al.
Trends in Endocrinology and Metabolism: Tem, 2018
Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
Baragetti A et al.
Pharmacological Research, 2018
The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
Gagnon A et al.
Obesity (silver Spring, Md.), 2016
A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.
Hawtin SR et al.
Molecular Endocrinology (baltimore, Md.), 2002
Select a paper to view details